Key result
Transsphenoidal surgery significantly improved mean flow-mediated vasodilatation from 5.3% to 7.4% (p=0.023) at 3 months in patients with active acromegaly.
Why the study?
Does transsphenoidal surgery improve endothelial dysfunction in patients with active acromegaly?
Observational (n=17)
Yes
Does transsphenoidal surgery improve endothelial dysfunction in patients with active acromegaly?
Absolute Event Rate: 7.4% vs 5.3%
p-value: p=0.023
Transsphenoidal surgery improves endothelial dysfunction in patients with active acromegaly, an effect that appears related to improvements in LDL-C and insulin resistance rather than direct reductions in GH or IGF-1.
May improve endothelial function in acromegaly; hypothesis-generating for metabolic mediation and requires randomized confirmation.
Flow-mediated vasodilatation (FMD) is a vascular functional test to detect endothelial dysfunction at the early stage of cardiovascular diseases. Patients with active acromegaly have higher morbidity and mortality due to cardiovascular events. To determine whether active acromegaly is associated with endothelial dysfunction, we studied 17 patients with active acromegaly for measurements of FMD, carotid intima-media thickness (IMT) and brachial-ankle pulse wave velocity (baPWV), and other biochemical parameters before and 3 months after transsphenoidal surgery (TSS). Baseline %FMD in patients with active acromegaly was significantly lower than that in age- and sex-matched control subjects. After TSS, the mean %FMD in acromegaly significantly increased from 5.3% to 7.4%; 12 patients had increased %FMD (responders), whereas 5 patients had decreased or unchanged %FMD (non-responders). However, neither carotid IMT nor baPWV changed after TSS. Serum levels of GH, insulin-like growth factor (IGF)-1, total cholesterol, low-density lipoprotein cholesterol (LDL-C), hemoglobin HA(1C), fasting plasma glucose and insulin levels, and homeostasis model assessment (HOMA)-R significantly decreased, whereas high-density lipoprotein cholesterol significantly increased. Responders had significantly lower baseline %FMD than did non-responders and both insulin levels and HOMA-R significantly decreased in responders, but not in non-responders after TSS. Simple regression analysis revealed that the change of %FMD showed a significant negative correlation with that of LDL-C, but not of IGF-1 or GH, in responders. In conclusion, it is suggested that endothelial dysfunction associated with active acromegaly improves soon after TSS, which is related to LDL-C and/or insulin resistance, but not to excess GH and/or IGF-1 itself.
No takes yet. Share an insight, caveat, or question.
Sakai et al. (2008) conducted an observational in Active acromegaly (n=17). Transsphenoidal surgery vs. Baseline (pre-surgery) was evaluated on Flow-mediated vasodilatation (%FMD) (p=0.023). Transsphenoidal surgery significantly improved mean flow-mediated vasodilatation from 5.3% to 7.4% (p=0.023) at 3 months in patients with active acromegaly.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: